Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
12 oct. 2021 16h01 HE
|
Prometheus Biosciences
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical...
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
11 août 2021 16h01 HE
|
Prometheus Biosciences
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn’s disease (CD) - - Phase 1a trial...
In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away
05 août 2021 07h30 HE
|
Prometheus Biosciences
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed...
Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
02 août 2021 08h00 HE
|
Prometheus Biosciences
- First Anti-TL1A trial in Crohn’s Disease - - APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal...
Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
19 juil. 2021 08h00 HE
|
Prometheus Biosciences
-First precision approach to IBD by utilizing a companion diagnostic to identify patients- -Phase 2a initiation in Crohn’s Disease on track for 3rd Quarter 2021- - Further details to be provided at...
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
15 juil. 2021 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Platform
21 juin 2021 09h00 HE
|
Prometheus Biosciences
-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Prometheus...
Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
25 mai 2021 16h05 HE
|
Prometheus Biosciences
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board
17 mai 2021 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference
14 mai 2021 16h01 HE
|
Prometheus Biosciences
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...